---
document_datetime: 2023-09-21 19:53:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_en.pdf
document_name: tavlesse-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.762617
conversion_datetime: 2025-12-21 19:36:13.003915
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number                    | (Invented) name   | Strength      | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging         | Pack size             |
|-----------------------------------|-------------------|---------------|---------------------------------------|---------------------------|-----------------------------|-----------------------|
| EU/1/19/1405/001 EU/1/19/1405/002 | Tavlesse Tavlesse | 100 mg 150 mg | Film-coated tablet Film-coated tablet | Oral use Oral use         | bottle (HDPE) bottle (HDPE) | 60 tablets 60 tablets |